|
" The Evaluation of New Antiarrhythmic Drugs Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: "
Morganroth, J.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
773971
|
| Doc. No
|
:
|
b593965
|
| Main Entry
|
:
|
Morganroth, J.
|
| Title & Author
|
:
|
The Evaluation of New Antiarrhythmic Drugs Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: : The Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricula.\ Morganroth, J.
|
| Publication Statement
|
:
|
Springer Verlag, 2013
|
| ISBN
|
:
|
9400982704
|
|
|
:
|
: 9789400982703
|
| Contents
|
:
|
How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- How to evaluate a new antiarrhythmic drug: The challenge of sudden cardiac death.- Pre-Clinical Evaluation of a New Antiarrhythmic Agent.- Relationships between effects on cardiac electrophysiology and antiarrhythmic efficacy.- What animal models should be used to define antiarrhythmic efficacy: acute dog models?.- Description of chronic canine myocardial infaction models suitable for the electropharmacologic evaluation of new antiarrhythmic drugs.- Non-canine animal models for evaluating antiarrhythmic efficacy General Group Discussion: Animal Models.- Defining the pharmacodynamics and pharmacokinetics of new antiarrhythmic drugs General Group Discussion: Pharmacology.- Chronic Studies in Patients with Non-Hemodynamically Significant Ventricular Arrhythmics.- How should Holter monitoring analysis be performed?.- Long-term ambulatory electrocardiographic recording in the determination of efficacy of new antiarrhythmic agents.- Evaluation of antiarrhythmic drugs. Should the Lown classification be used as a measure of efficacy?.- General Group Discussion: Holter Monitoring.- Study Designs: Chronic Patients.- New means of evaluating antiarrhythmic drugs.- Parallel or crossover designs in evaluation of antiarrhythmic therapy.- General Group Discussion: Study Designs: Chronic Patients.- Remarks: J. Richard Crout, Director, Bureau of Drugs Food and Drug Administration.- Acute Studies in Patients with Hemodynamically Significant Significant Ventricular Arrhythmias.- Acute drug testing as a part of a systematic approach to antiarrhythmic drug therapy.- What is the role of electrophysiology in drug testing? General Group Discussion: Electrophysiology.- What should the study design be to test new antiarrhythmic drugs in patients with acute myocardial infarction, digitalis toxicity and other acute problems General Group Discussion: Study Designs in Acute Patients.- Special Considerations.- What baseline electrophysiologic data should be obtained (plus discussion).- Assessment of the hemodynamic and inotropic effects of antiarrhythmic drugs (plus discussion).- Evaluation of drug treatment in supraventricular arrhythmias (plus discussion).- How should long-term safety of a new antiarrhythmic drug be defined (plus discussion).- How should one manage emergency drug requests and their data (puls discussion).- How does one evaluate and use outside U.S.A. data in the new drug application (plus discussion).
|
| LC Classification
|
:
|
RC685.A65M674 2013
|
| Added Entry
|
:
|
Dreifus, L.S.
|
|
|
:
|
Michelson, E.L.
|
|
|
:
|
Moore, E. Neil
|
|
|
:
|
Morganroth, J.
|
| |